eversea

Eversea Confirms Launch of the World's First Organic Omega-3 DHA Supplement Across USA

(TheNewswire)



SOLARVEST BIOENERGY INC. (TSXV:SVS) ("Solarvest" or the " Company " ), is pleased to provide an update to the December 21, 2020 press release of its highly-bioavailable Organic Omega-3 Children's Supplement. The product, marketed under the Company's Eversea brand, is the world's first and only Organic Omega-3 children's fruit drop. Eversea seeks to benefit from the extensive and growing market demand for organic, vegetarian and vegan diets.  Eversea's organically certified supplement holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, establishing a new market segment for Organic Omega-3 nutraceuticals

The Eversea Organic Omega-3 Fruit Drop is now available to health conscientious customers throughout the USA directly from its e-commerce web site at https://eversea.ca/ and Amazon.  This initial Children's Omega-3 supplement, being Non-GMO, USDA Organic and EU Organic Certified is a unique and a premium entry product that is positioned to take advantage of the significant and growing demand for plant-based products.  Eversea's Organic Omega-3 is over 80% dried fruit, contains no added sugar, tests free from all common allergens and contains the Company's patented and highly bioavailable O rganic Omega-3 DHA powder.

"This Organic Omega-3 Children's Fruit Drop will appeal to customers looking for a sustainably sourced and organic product, without any nutrient-degrading industrial processing or chemicals. This process yields a pure, whole food Omega-3 with higher bioavailability than flaxseed or hemp which only contain ALA Omega-3. Parents can see a clean ingredient label and feel good about feeding their children a wholesome and healthy supplement," said Gerri Greenham, President and CEO of Solarvest.  He continued," Our Omega-3 is truly sustainable and produced using organic strains of algae.  Eversea specifically set out to reduce the pressure on marine species for harvesting Omega-3 and beneficially this process also ensures that our Organic ingredient is free from any contaminants which may be present in our oceans today."

The Company further reports that a second product run with its German-based organically certified manufacturer has now successfully concluded. Beyond the Company's intent to supplement inventory levels, this second Organic DHA ingredient batch will be offered to interested parties both inside and outside North America who have already shown interest in the Organic Omega-3 products. In addition to Company-driven product alternatives, Eversea is engaged to advance the development of a second adolescent offering to complement its Natural Fruit Drop. This product is anticipated to provide organic oriented retailers with house branded products using Eversea's  Omega-3 DHA active ingredient to provide a patented competitive advantage.

The Company is reaching out to larger established distributors to secure a distribution pipeline for its Organic Omega-3 products under the Company's "Eversea Brand" or other "Home Brands" to achieve scalability and allow the Company to readily market their Organic Omega-3 products.

Corporate

The company also announces that Greg Drohan (see press release dated January 5, 2021) has officially joined the Board of Directors and that Ken Cawkell has resigned from the Board of Directors after many years of valuable service. We thank him for his invaluable contributions and continued support as he will remain on as the corporate lawyer for the Company.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×